Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2021-10-22 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司关于召开2021年第三次临时股东大会的通知
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a notice about convening the 2021 third extraordinary general meeting of shareholders (临时股东大会) for 圣湘生物科技股份有限公司. It details the meeting date, voting methods, agenda items including stock incentive plans and amendments to the company charter, and instructions for shareholders to attend and vote. It does not contain financial statements or results, nor is it a transcript or presentation. It is an announcement of a shareholders meeting, specifically a notice to shareholders about the meeting and voting procedures. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting and voting procedures rather than the solicitation materials or proxy statement, it aligns best with Declaration of Voting Results & Voting Rights Announcements (DVA) as it relates to voting rights and meeting details. The document length is 3166 characters, which is relatively short and consistent with a meeting notice rather than a full report or presentation.
2021-10-22 Chinese
圣湘生物2021年限制性股票激励计划（草案）
Remuneration Information Classification · 95% confidence The document is titled "2021 年限制性股票激励计划（草案）" which translates to "2021 Restricted Stock Incentive Plan (Draft)". It details a stock incentive plan involving restricted stock awards to directors, senior management, core technical personnel, and other key employees. The document includes detailed provisions on the purpose, scope, management, grant price, vesting schedule, and legal compliance of the stock incentive plan. It is a comprehensive plan document rather than a brief announcement or a report of voting results. It is not an annual or quarterly financial report, nor an earnings release or audit report. It is also not a proxy solicitation or remuneration report, but rather a detailed management plan related to stock incentives. This type of document fits best under the category of "Remuneration Information" (DEF 14A), which covers reports detailing compensation plans for executives and directors, including stock incentive plans.
2021-10-22 Chinese
圣湘生物科技股份有限公司2021年限制性股票激励计划首次授予激励对象名单（更新后）
Remuneration Information Classification · 95% confidence The document is titled '2021 年限制性股票激励计划首次授予激励对象名单（更新后）' which translates to '2021 Restricted Stock Incentive Plan First Grant Incentive Object List (Updated)'. It lists names, positions, and quantities of restricted stock granted to directors, senior management, and key technical personnel. This is a detailed announcement of stock incentive grants to management and key employees, which is related to remuneration and compensation information. It is not a full annual report, audit report, or earnings release. It is not a proxy solicitation or voting result announcement. The document is short (1368 characters) and contains detailed data on stock incentives granted. Therefore, the best fitting category is Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors, including stock incentive plans.
2021-10-22 Chinese
圣湘生物科技股份有限公司2021年限制性股票激励计划首次授予激励对象名单
Share Issue/Capital Change Classification · 95% confidence The document is a list of recipients for a restricted stock incentive plan granted by the company in 2021. It details the names, positions, and quantities of restricted stock awarded to directors, senior management, core technical personnel, and other employees. This type of document is related to share-based compensation and insider incentives rather than financial results, governance structure, or regulatory filings. It is not an annual report, earnings release, or management discussion. It is also not a director's dealing report since it covers a broad group and is about an incentive plan grant, not personal share transactions. The document is an announcement of a share issue related to stock incentives. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length is short but contains substantive information about the share incentive plan grant, not just an announcement of a report publication or a regulatory filing. Confidence is high due to clear content about restricted stock grants and share capital impact.
2021-10-21 Chinese
圣湘生物科技股份有限公司2021年限制性股票激励计划（草案）摘要公告
Remuneration Information Classification · 95% confidence The document is a detailed announcement regarding a 2021 restricted stock incentive plan (股权激励计划) for 圣湘生物科技股份有限公司. It includes comprehensive information about the stock incentive plan's purpose, scope, number of shares, pricing, eligibility, vesting conditions, performance targets, and procedural details. The content is regulatory and governance-related, focusing on management compensation and incentive mechanisms rather than financial results or earnings. It is not a full annual or quarterly report, audit report, earnings release, or call transcript. It is not a proxy solicitation or voting results announcement. The document is a formal disclosure of a stock-based remuneration plan for executives and key personnel, which fits the definition of Remuneration Information (DEF 14A) filings that detail compensation and incentive plans for top executives and directors. The document length and detail confirm it is the plan itself, not just an announcement of a report. Therefore, the appropriate classification is Remuneration Information (DEF 14A).
2021-10-21 Chinese
圣湘生物科技股份有限公司第一届监事会2021年第七次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a supervisory board meeting of 圣湘生物科技股份有限公司 (Shengxiang Bio-tech Co., Ltd.) regarding the company's 2021 restricted stock incentive plan. It details the meeting attendance, the approval of the stock incentive plan draft, the implementation assessment methods, and the verification of the initial list of incentive recipients. The document includes voting results and mentions that these matters will be submitted to the shareholders' meeting for approval. There is no financial data, no full report, no earnings or audit information, and no regulatory certification. The document is a formal announcement of board/management decisions related to stock incentive plans, which falls under Board/Management Information (MANG). The document length is short (1873 characters), and it is not a report publication announcement or a regulatory filing. Therefore, the best classification is MANG with high confidence.
2021-10-21 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.